Amyloid Vaccine AV-1959R Generates Antibodies in All Phase 1 Recipients

20 Oct 2026 0 comments

In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.

Source: NeurologyLive Published 20 Oct 2026 Imported 20 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment